The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells.

Animals Apoptosis Cell Cycle Checkpoints / genetics Cell Line, Tumor Cell Proliferation / genetics Deoxycytidine / analogs & derivatives Mice MicroRNAs / genetics Pancreatic Neoplasms / drug therapy Xenograft Model Antitumor Assays Gemcitabine
Pancreatic neoplasm cell cycle cyclin gemcitabine microRNA

Journal

In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809

Informations de publication

Date de publication:
Historique:
received: 28 05 2020
revised: 24 07 2020
accepted: 27 07 2020
entrez: 4 11 2020
pubmed: 5 11 2020
medline: 22 6 2021
Statut: ppublish

Résumé

Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. We evaluated the effect of gemcitabine on the cell cycle of PDAC cells in vitro and in vivo and on the miRNA expression profile. Effects of gemcitabine on PK-1 and PK-9 cell growth were evaluated using a cell counting kit-8 assay. Xenografted mouse models were used to assess gemcitabine effects in vivo. Gemcitabine inhibited the proliferation and tumour growth of PK-1 cells, and induced S phase cell cycle arrest. Numerous miRNAs were altered upon gemcitabine treatment of PK-1 cells and xenograft models. Altered miRNAs may serve as potential therapeutic targets for improving the efficacy of gemcitabine in PDAC.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Gemcitabine, an inhibitor of DNA synthesis, is the gold standard chemotherapeutic agent for pancreatic ductal adenocarcinoma (PDAC). MicroRNAs (miRNAs) play critical roles in cancers, including PDAC. However, less is known about the effect of gemcitabine on PDAC cells and miRNA expression in PDAC. We evaluated the effect of gemcitabine on the cell cycle of PDAC cells in vitro and in vivo and on the miRNA expression profile.
MATERIALS AND METHODS METHODS
Effects of gemcitabine on PK-1 and PK-9 cell growth were evaluated using a cell counting kit-8 assay. Xenografted mouse models were used to assess gemcitabine effects in vivo.
RESULTS RESULTS
Gemcitabine inhibited the proliferation and tumour growth of PK-1 cells, and induced S phase cell cycle arrest. Numerous miRNAs were altered upon gemcitabine treatment of PK-1 cells and xenograft models.
CONCLUSION CONCLUSIONS
Altered miRNAs may serve as potential therapeutic targets for improving the efficacy of gemcitabine in PDAC.

Identifiants

DOI: 10.21873/invivo.12155 PMID: 33144424 PMC: PMC7811671
pubmed: 33144424
pii: 34/6/3195
doi: 10.21873/invivo.12155
pmc: PMC7811671
doi:

Substances chimiques

MicroRNAs 0
Deoxycytidine 0W860991D6
Gemcitabine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3195-3203

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Références

Hepatol Res. 2015 Jan;45(2):128-41
pubmed: 25040738
Anticancer Res. 2006 Jul-Aug;26(4B):3017-24
pubmed: 16886629
Int J Oncol. 2015 Aug;47(2):535-42
pubmed: 26060089
N Engl J Med. 2004 Mar 18;350(12):1200-10
pubmed: 15028824
Clin Cancer Res. 2012 Feb 15;18(4):981-92
pubmed: 22114139
World J Surg Oncol. 2016 Sep 06;14(1):239
pubmed: 27595705
Br J Cancer. 2013 Feb 5;108(2):361-9
pubmed: 23329235
Genes Cancer. 2013 Jan;4(1-2):61-9
pubmed: 23946872
Int J Oncol. 2015 Oct;47(4):1293-302
pubmed: 26252371
Cancer Res. 2005 Aug 1;65(15):6835-42
pubmed: 16061666
Cell. 1994 Nov 18;79(4):551-5
pubmed: 7954821
J Clin Oncol. 1997 Jun;15(6):2403-13
pubmed: 9196156
Gastroenterology. 2006 Jun;130(7):2113-29
pubmed: 16762633
Mol Cancer Ther. 2013 Jan;12(1):83-93
pubmed: 23171948
Oncology. 1998 Jul-Aug;55(4):363-9
pubmed: 9663429
Cancer Sci. 2007 Jul;98(7):1128-36
pubmed: 17489984
Biomed J. 2013 Sep-Oct;36(5):200-8
pubmed: 24225187
Nat Rev Genet. 2012 Mar 13;13(4):271-82
pubmed: 22411466
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Exp Ther Med. 2019 Aug;18(2):997-1004
pubmed: 31316597
Am J Health Syst Pharm. 1997 Jan 15;54(2):162-70; quiz 197-8
pubmed: 9117804
Clin Gastroenterol Hepatol. 2004 Mar;2(3):252-61
pubmed: 15017610
World J Gastroenterol. 2015 Apr 28;21(16):4788-801
pubmed: 25944992
Oncogene. 2016 Apr 21;35(16):2031-9
pubmed: 26234680
Int J Cancer. 2002 Feb 1;97(4):439-45
pubmed: 11802204
Cancer Res. 1997 May 1;57(9):1634-7
pubmed: 9134998
Drug Resist Updat. 2015 Nov;23:55-68
pubmed: 26690340
Cancer Chemother Pharmacol. 2013 Sep;72(3):553-63
pubmed: 23835677
Acta Pharmacol Sin. 2013 Jul;34(7):870-9
pubmed: 23624759
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947
pubmed: 31648972
Oncol Rep. 2016 Dec;36(6):3488-3496
pubmed: 27779693
Int J Cancer. 2001 Aug 1;93(3):401-8
pubmed: 11433406
JAMA. 2007 Jan 17;297(3):267-77
pubmed: 17227978
Hepatobiliary Pancreat Dis Int. 2012 Jun;11(3):319-24
pubmed: 22672828
J Gastrointest Surg. 2004 Dec;8(8):1072-8
pubmed: 15585396

Auteurs

Daisuke Namima (D)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Shintaro Fujihara (S)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Hisakazu Iwama (H)

Life Science Research Center, Kagawa University, Kagawa, Japan.

Koji Fujita (K)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Takanori Matsui (T)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Mai Nakahara (M)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Megumi Okamura (M)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Masahiro Hirata (M)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Toshiaki Kono (T)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Naoki Fujita (N)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Hiroki Yamana (H)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Kiyohito Kato (K)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Hideki Kamada (H)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Asahiro Morishita (A)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Hideki Kobara (H)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Kunihiko Tsutsui (K)

Life Science Research Center, Kagawa University, Kagawa, Japan.

Tsutomu Masaki (T)

Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan tmasaki@med.kagawa-u.ac.jp.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Cycle cellulaire › Points de contrôle du cycle cellulaire › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxycytidine › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › The Effect of Gemcitabine on Cell Cycle Arrest...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Gemcitabine › The Effect of Gemcitabine on Cell Cycle Arrest...